Eversept Partners’s Immunomedics Inc IMMU Stock Holding History

Eversept Partners’s Portfolio IMMU Stock Details IMMU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-55,000	Closed	-$1.3M	–	82
2018 Q2	$1.3M	Buy	+55,000	New	+$1.11M	0.6%	36

Other funds holding IMMU

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Eversept Partners's IMMU Position: Q3 2018 in Review

Eversept Partners sold out of Immunomedics Inc (IMMU) in Q3 2018, closing a stake of 55,000 shares — an estimated $1.3M sold.

Eversept Partners first reported a position in IMMU in Q2 2018 and held it in 1 quarter. The position peaked at $1.3M in Q2 2018. 207 funds tracked by Wall St. Rank hold IMMU as of Q3 2018.

Eversept Partners reported no remaining Immunomedics Inc position as of Q3 2018 after selling out during the quarter.
Eversept Partners sold 55,000 Immunomedics Inc shares in Q3 2018, an estimated $1.3M.
Eversept Partners first reported a position in Immunomedics Inc in Q2 2018 and held it in 1 quarter.
Eversept Partners's Immunomedics Inc position peaked at $1.3M in Q2 2018.
207 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2018.

Based on Eversept Partners's 13F filing for Q3 2018, filed 14 Nov 2018.